Current and emerging pharmacotherapies for hereditary hemorrhagic telangiectasia

References

• Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91:66–67. [PubMed PMID: 10751092].
   Google Scholar
• Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment [Review]. Blood Rev. 2010;24:203–219. [PubMed PMID: 20870325].
   Google Scholar
• Shovlin CL. Pulmonary arteriovenous malformations [Review]. Am J Respir Crit Care Med. 2014;190:1217–1228. [PubMed PMID: 25420112]. DOI:10.1164/rccm.201407-1254CI
   Google Scholar
• Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med. 1999;245:31–39. [PubMed PMID: 10095814].
   Google Scholar
• Jessurun GA, Kamphuis DJ, van der Zande FH, et al. Cerebral arteriovenous malformations in The Netherlands Antilles. High prevalence of hereditary hemorrhagic telangiectasia-related single and multiple cerebral arteriovenous malformations. Clin Neurol Neurosurg. 1993;95:193–198. [PubMed PMID: 8242961].
   Google Scholar
• McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8:345–351. [PubMed PMID: 7894484].
   Google Scholar
• Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996;13:189–195. [PubMed PMID: 8640225].
   Google Scholar
• Gallione CJ, Repetto GM, Legius E, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet. 2004;363:852–859. [PubMed PMID: 15031030].
   Google Scholar
• Cole SG, Begbie ME, Wallace GM, et al. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet. 2005;42:577–582. [PubMed PMID: 15994879].
   Google Scholar
• Bayrak-Toydemir P, McDonald J, Akarsu N, et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A. 2006;140:2155–2162. [PubMed PMID: 16969873].
   Google Scholar
• Wooderchak-Donahue WL, McDonald J, O’Fallon B, et al. BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am J Hum Genet. 2013;93:530–537. [PubMed PMID: 23972370].
   Google Scholar
• Morales-Angulo C, del Valle-Zapico A. Hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg. 1998;119:293. [PubMed PMID: 9743086].
   Google Scholar
• Assar OS, Friedman CM, White RI Jr. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 1991;101:977–980. [PubMed PMID: 1886446].
   Google Scholar
• Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;333:918–924. [PubMed PMID: 7666879].
   Google Scholar
• Ingrosso M, Sabbà C, Pisani A, et al. Evidence of small-bowel involvement in hereditary hemorrhagic telangiectasia: a capsule-endoscopic study. Endoscopy. 2004;36:1074–1079. [PubMed PMID: 15578297].
   Google Scholar
• Vase P, Grove O. Gastrointestinal lesions in hereditary hemorrhagic telangiectasia. Gastroenterology. 1986;91:1079–1083. [PubMed PMID: 3489651].
   Google Scholar
• Geisthoff UW, Schneider G, Fischinger J, et al. Hereditary haemorrhagic telangiectasia Osler´s disease, an interdisciplinary challenge. Hno. 2002;50:114–128. [PubMed PMID: 12080621].
   Google Scholar
• Albiñana V, Bernabeu-Herrero ME, Zarrabeitia R, et al. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells. Thromb Haemost. 2010;103:525–534. [PubMed PMID:20135064].
   Google Scholar
• Zarrabeitia R, Ojeda-Fernandez L, Recio L, et al. Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia. Thromb Haemost. 2016;115:1167–1177. [PubMed PMID: 26818701].
   Google Scholar
• Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. Jama. 2012;307:948–955. [PubMed PMID: 22396517].
   Google Scholar
• Whitehead KJ, Sautter NB, McWilliams JP, et al. Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial. Jama. 2016;316:943–951. [PubMed PMID:27599329].
   Google Scholar
• Dupuis-Girod S, Ambrun A, Decullier E, et al. Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangectasia: a randomized clinical trial. Jama. 2016 Sep 6;316(9):934–942. [PubMed PMID: 27599328].
   Google Scholar
• Albiñana V, Recio-Poveda L, Zarrabeitia R, et al. Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia. Thromb Haemost. 2012;108:41–53. [PubMed PMID: 22552254].
   Google Scholar
• Saba HI, Morelli GA, Logrono LA. Brief report: treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N Engl J Med. 1994;330:1789–1790. [PubMed PMID: 8190155].
   Google Scholar
• Annichino-Bizzacchi JM, Facchini RM, Torresan MZ, et al. Hereditary hemorrhagic telangiectasia response to aminocaproic acid treatment. Thromb Res. 1999;96:73–76. [PubMed PMID: 10554087].
   Google Scholar
• Korzenik JR, Topazian MD, White R. Treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N Eng J Med. 1994;331:1236. [PubMed PMID: 7935675].
   Google Scholar
• Kwaan HC, Silverman S. Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia. Arch Dermatol. 1973;107:571–573. [PubMed PMID:4697687].
   Google Scholar
• Watanabe M, Hanawa S, Morishima T. Fibrinolytic activity in cutaneous lesions of hereditary hemorrhagic telangiectasia. Nippon Hifuka Gakkai Zasshi. 1985;95:11–16. [PubMed PMID: 4039768].
   Google Scholar
• Manucci PM. Hemostatic drugs. N Engl J Med. 1998;339:245–253. [PubMed PMID: 9673304].
   Google Scholar
• Sabbà C, Gallitelli M, Palasciano G. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med. 2001;345:926. [PubMed PMID: 11565536].
   Google Scholar
• Klepfish A, Berrebi A, Schattner A. Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia. Arch Intern Med. 2001;161:767. [PubMed PMID: 11231712].
   Google Scholar
• Fernandez-L A, Garrido-Martin EM, Sanz-Rodriguez F, et al. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. Thromb Haemost. 2007;97:254–262. [PubMed PMID: 17264955].
   Google Scholar
• Pérez del Molino A, Zarrabeitia R, Fernández A, et al. Efficacy of tranexamic acid in a patient with hereditary hemorrhagic telangiectasia and massive epistaxis. Med Clin (Barc). 2004;123:118–119. [PubMed PMID: 15225479].
   Google Scholar
• Shovlin CL, Sulaiman NL, Govani FS, et al. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost. 2007;98:1031–1039. [PubMed PMID: 18000608].
   Google Scholar
• Gaillard S, Dupuis-Girod S, Boutitie F, et al., ATERO Study Group. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12:1494–1502. [PubMed PMID: 25040799].
   Google Scholar
• Geisthoff UW, Seyfert UT, Kübler M, et al. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid – a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res. 2014;134:565–571. [PubMed PMID: 25005464].
   Google Scholar
• Longacre AV, Gross CP, Gallitelli M, et al. Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol. 2003;98:59–65. [PubMed PMID: 12526937].
   Google Scholar
• Haq AU, Glass J, Netchvolodoff CV, et al. Hereditary hemorrhagic telangiectasia and danazol. Ann Intern Med. 1988;109:171. [PubMed PMID: 3382114].
   Google Scholar
• Korzenik JR. Hereditary hemorrhagic telangiectasia and other intestinal vascular anomalies. Gastroenterologist. 1996;4:203–210. [PubMed PMID 8891684].
   Google Scholar
• Jameson JJ, Cave DR. Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagictelangiectasia. Laryngoscope. 2004;114:705–709. [PubMed PMID: 15064628].
   Google Scholar
• Zacharski LR, Dunbar SD, Newsom WA Jr. Hemostatic effects of tamoxifen in HHT. Thromb Haemostas. 2001;85:371–372. [PubMed PMID: 11246565].
   Google Scholar
• Yaniv E, Preis M, Hadar T, et al. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope. 2009;119:284–288. [PubMed PMID:19160429].
   Google Scholar
• Yaniv E, Preis M, Shevro J, et al. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial. Rhinology. 2011;49:214–216. [PubMed PMID: 21743879].
   Google Scholar
• Kim H, Peterson TG, Barnes S. Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways [Review]. Am J Clin Nutr. 1998;68(6 Suppl):1418S–1425S. [PubMed PMID: 9848510].
   Google Scholar
• Albiñana V. PhD Ensayos Preclínicos in vitro con células endoteliales como aproximaciones terapéuticas farmacológicas para la telangiectasia hemorrágica hereditaria. Spain: Universidad Complutense de Madrid; 2012. Available from: http://eprints.ucm.es/16666/1/T34001.pdf
   Google Scholar
• Albiñana V, Sanz-Rodríguez F, Recio-Poveda L, et al. Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-β1 signaling in endothelial cells. Mol Pharmacol. 2011;79:833–843. [PubMed PMID: 21310938].
   Google Scholar
• Skaro AI, Marotta PJ, McAlister VC. Regression of cutaneous and gastrointestinal telangiectasia in a patient with hereditary hemorrhagic telangiectasia. Ann Intern Med. 2006;144:226–227. [PubMed PMID: 16461979].
   Google Scholar
• de Gussem EM, Snijder RJ, Disch FJ, et al. The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study. Rhinology. 2009;47:85–88. [PubMed PMID: 19382502].
   Google Scholar
• Toporsian M, Gros R, Kabir MG, et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res. 2005 Apr 1;96(6):684–692. [Epub 2005 Feb 17. PubMed PMID: 15718503].
   Google Scholar
• Zemankova L, Varejckova M, Dolezalova E, et al. Atorvastatin-induced endothelial nitric oxide synthase expression in endothelial cells is mediated by endoglin. J Physiol Pharmacol. 2015;66:403–413. [PubMed PMID: 26084222].
   Google Scholar
• Roy H, Bhardwaj S, Ylä-Herttuala S. Biology of vascular endothelial growth factors. FEBS Letters. 2006;580:2879–2887. [PubMed PMID: 16631753].
   Google Scholar
• Cirulli A, Liso A, D’Ovidio F, et al. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol. 2003;110:29–32. [PubMedPMID: 12975554].
   Google Scholar
• Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor beta1 as well as high ALK1 tissue expression. Haematologica. 2005;90:818–828. [PubMed PMID: 16330439].
   Google Scholar
• Peng HL, Hu GY, Zhang GS, et al. Analysis of angiogenesis related proteins and its implication in type-2 hereditary hemorrhagic telangiectasia. ZhonghuaXue Ye XueZaZhi. 2006;27:616–620. [PubMed PMDI: 17278429].
   Google Scholar
• Botella LM, Albiñana V, Ojeda-Fernandez L, et al. Research on potential biomarkers in hereditary hemorrhagic telangiectasia. Front Genet. 2015;6:115–120. [PubMed. PMID: 25873934].
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342. [PubMed PMID: 15175435].
   Google Scholar
• Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035–1047. [PubMed PMID: 15936441].
   Google Scholar
• Mitchell A, Adams L, MacQuillan G, et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transplant. 2008;14:210–213. [PubMedPMID: 18236396].
   Google Scholar
• Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol. 2006;85:631–632. [PubMed PMID: 16807748].
   Google Scholar
• Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2009 May 14;360(20):2143–2144. [PubMed PMID: 19439755]. DOI:10.1056/NEJMc0901421
   Google Scholar
• Oosting S, Nagengast W, de Vries E. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2009 Aug 27;361(9):931; author reply 931–932. [PubMed PMID: 19710496]. DOI:10.1056/NEJMc091271
   Google Scholar
• Brinkerhoff BT, Poetker DM, Choong NW. Long-term therapy with bevacizumab inhereditary hemorrhagic telangiectasia. N Engl J Med. 2011 Feb 17;364(7):688–689. [PubMed PMID: 21323562]. DOI:10.1056/NEJMc1012774
   Google Scholar
• Fodstad P, Dheyauldeen S, Rinde M, et al. Anti-VEGF with3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia. Ann Hematol. 2011 May;90(5):611–612. [Epub 2010 Sep 8. PubMed PMID: 20824275; PubMed Central PMCID: PMC3070877]. DOI:10.1007/s00277-010-1063-5
   Google Scholar
• Lazaraki G, Akriviadis E, Pilpilidis I, et al. Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia. Am J Gastroenterol. 2011 Dec;106(12):2204–2206. [PubMed PMID: 22138950]. DOI:10.1038/ajg.2011.287
   Google Scholar
• Suppressa P, Liso A, Sabbà C. Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia. Br J Haematol. 2011 Feb;152(4):365.
   Google Scholar
• Young LH, Henderson KJ, White RI, et al. Bevacizumab: finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia. Hepatology. 2013 Jul;58(1):442–445. [Epub 2013 May 31. PubMed PMID: 23686865]. DOI:10.1002/hep.26472
   Google Scholar
• Dupuis-Girod S, Buscarini E. Hereditary hemorrhagic telangiectasia: to transplant or not to transplant? Liver Int. 2016;36:1741–1744. [PubMed PMID: 27864870].
   Google Scholar
• Arizmendez NP, Rudmik L, Poetker DM. Intravenous bevacizumab for complication of hereditary hemorrhagic telangiectasia: a review of the literature [Review]. Int Forum Allergy Rhinol. 2015;5:1042–1047. [PubMed PMID: 26202958].
   Google Scholar
• Ou G, Galorport C, Enns R. Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia. World J Gastrointest Surg. 2016;8:792–795. [PubMed PMID: 28070235].
   Google Scholar
• Karnezis TT, Davidson TM. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope. 2012;122:495–497. [PubMed PMID: 22147664].
   Google Scholar
• Kim YH, Kim MJ, Choe SW, et al. Selective effects of oral anti-angiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia. J Thromb Haemost. 2017 Mar 24;15:1095–1102. [Epub ahead of print] [PubMed PMID: 28339142].
   Google Scholar
• Faughnan ME, Murali C, Gossage JR, et al. Evaluation of pazopanib on bleeding in subjects with HHT: rationale and design of phase II trial [Abstracts]. In 11th HHT International Scientifc Conferencia; 2015 Jun 11–14; Captiva, Fl.
   Google Scholar
• Kersemaerkers MAH, Westermann CJJ, Mager JJ, et al. Thalidomide for the treatment of epistaxis.A review on clinical management and pharmacological therapy current vascular pharmacology, 2010, vol. 8, no. 4 9 in hereditary haemorrhagic telangiectasia. Hematol Meet Rep. 2007;1:22–23.
   Google Scholar
• Lebrin F, Srun S, Raymond K, et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med. 2010;16:420–428. [PubMed PMID: 20364125].
   Google Scholar
• Franchini M, Frattini F, Crestani S, et al. Novel treatments for epistaxis in hereditary hemorrhagic telangiectasia: a systematic review of the clinical experience with thalidomide. J Thromb Thrombolysis. 2013;36(3):355–357. [PubMed PMID: 23143669].
   Google Scholar
• Invernizzi R, Quaglia F, Klersy C, et al. Efficacy and safety of thalidomide for the treatmentof severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. Lancet Haematol. 2015 Nov;2(11):e465–73. [Epub 2015 Oct 27. PubMed PMID: 26686256]. DOI:10.1016/S2352-3026(15)00195-7
   Google Scholar
• Colombo G, Bortolotti F, Chiapponi V, et al. Nasalpowders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia. Int J Pharm. 2016 Nov 30;514(1):229–237. [PubMed PMID: 27863666]. DOI:10.1016/j.ijpharm.2016.07.002
   Google Scholar
• Olitsky SE. Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Am J Otolaryngol. 2012;33:375–376. [PubMed PMID 22079094].
   Google Scholar
• Ichimura K, Kikuchi H, Imayoshi S, et al. Topical application of timolol decreases the severity and frequency of epistaxis in patients who have previously undergone nasal dermoplasty for hereditary hemorrhagic telangiectasia. Auris Nasus Larynx. 2016;43:429–432. [PubMed PMID: 26739947].
   Google Scholar
• Epperla N, Brilliant MH, Vidaillet H. Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants. BMJ Case Rep. 2014 Feb 11;2014:bcr2013203056. [PubMed PMID: 24518395].
   Google Scholar
• Botella LM, Zarrabeita-Puente R, Albiñana V, et al. Efficacy of topical timolol for the treatment of mucocutaneous telangiectases in patients with HHT [Abstracts]. 11th HHT International Scientifc Conferencia; 2015 Jun 11–14; Captiva, Fl.
   Google Scholar
• Mei-Zahav M, Blacu Hannah MD, Goldschmidt NMD. Topical propranolol treatment for severe epistaxis in HHT [Abstracts]. 11th HHT International Scientifc Conferencia; 2015 Jun 11–14; Captiva, Fl.
   Google Scholar
• Albiñana V, Villar Gómez de Las Heras K, Serrano-Heras G, et al. Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients. Orphanet J Rare Dis. 2015;10:118–125. [PubMed PMID: 26394686].
   Google Scholar